image
Healthcare - Drug Manufacturers - General - NYSE - CH
$ 110.55
-2.24 %
$ 218 B
Market Cap
18.83
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NVS stock under the worst case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NVS stock under the base case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NVS stock under the best case scenario is HIDDEN Compared to the current market price of 111 USD, Novartis AG is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVS

image
$115.0$115.0$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
51.7 B REVENUE
10.85%
14.5 B OPERATING INCOME
48.88%
11.9 B NET INCOME
39.28%
17.6 B OPERATING CASH FLOW
21.86%
-7.51 B INVESTING CASH FLOW
-134.26%
-11.7 B FINANCING CASH FLOW
17.76%
13.6 B REVENUE
0.46%
4.66 B OPERATING INCOME
32.10%
3.61 B NET INCOME
27.96%
3.64 B OPERATING CASH FLOW
-13.07%
330 M INVESTING CASH FLOW
110.88%
-8.55 B FINANCING CASH FLOW
-185.31%
Balance Sheet Novartis AG
image
Current Assets 29.7 B
Cash & Short-Term Investments 13.4 B
Receivables 9.54 B
Other Current Assets 6.81 B
Non-Current Assets 72.5 B
Long-Term Investments 1.13 B
PP&E 10.9 B
Other Non-Current Assets 60.5 B
13.06 %9.33 %6.66 %10.63 %59.21 %Total Assets$102.2b
Current Liabilities 28.7 B
Accounts Payable 4.57 B
Short-Term Debt 8.32 B
Other Current Liabilities 15.8 B
Non-Current Liabilities 29.4 B
Long-Term Debt 22.9 B
Other Non-Current Liabilities 6.49 B
7.87 %14.32 %27.18 %39.46 %11.17 %Total Liabilities$58.1b
EFFICIENCY
Earnings Waterfall Novartis AG
image
Revenue 51.7 B
Cost Of Revenue 12.8 B
Gross Profit 38.9 B
Operating Expenses 24.4 B
Operating Income 14.5 B
Other Expenses 2.6 B
Net Income 11.9 B
60b60b50b50b40b40b30b30b20b20b10b10b0052b(13b)39b(24b)15b(3b)12bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.20% GROSS MARGIN
75.20%
28.12% OPERATING MARGIN
28.12%
23.09% NET MARGIN
23.09%
27.11% ROE
27.11%
11.68% ROA
11.68%
15.55% ROIC
15.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Novartis AG
image
14b14b12b12b10b10b8b8b6b6b4b4b2b2b0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 11.9 B
Depreciation & Amortization 6.07 B
Capital Expenditures -3.81 B
Stock-Based Compensation 1.04 B
Change in Working Capital -706 M
Others -1.87 B
Free Cash Flow 13.8 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Novartis AG
image
Wall Street analysts predict an average 1-year price target for NVS of $120 , with forecasts ranging from a low of $118 to a high of $121 .
NVS Lowest Price Target Wall Street Target
118 USD 6.74%
NVS Average Price Target Wall Street Target
120 USD 8.25%
NVS Highest Price Target Wall Street Target
121 USD 9.45%
Price
Max Price Target
Min Price Target
Average Price Target
12512512012011511511011010510510010095959090Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
2.45% DIVIDEND YIELD
3.99 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
4.000004.000003.500003.500003.000003.000002.500002.500002.000002.000001.500001.500001.000001.000000.500000.500000.000000.000002.524192.522.474912.472.460572.462.667562.672.56722.573.0423.043.37843.383.3573.363.469363.473.77723.783.9943.992015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Novartis AG
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion BioNTech SE  BNTX on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02. benzinga.com - 2 weeks ago
Novartis (NVS) is a Great Momentum Stock: Should You Buy? Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 2 weeks ago
Why Novartis (NVS) is a Great Dividend Stock Right Now Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? zacks.com - 2 weeks ago
BioNTech says Novartis executive Zapata-Gomez to become CFO German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1. reuters.com - 2 weeks ago
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million Novartis AG NVS agreed to acquire Regulus Therapeutics Inc.  RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion. benzinga.com - 2 weeks ago
Why Novartis (NVS) is a Top Value Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com - 2 weeks ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. zacks.com - 2 weeks ago
Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US investment, bolstering our positive outlook amid pharma tariff uncertainties. It also raised its FY 2025 outlook. Despite patent expirations, Novartis' strong cash flow, ongoing buyback, and low-risk profile support our continued buy rating. seekingalpha.com - 2 weeks ago
Adakveo Market Epidemiology, Pipeline Analysis, Market Insights & Forecasts Report 2025, with Focus on Novartis In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. Novartis AG leads, with North America as the largest market and Asia-Pacific fastest-growing. In-depth Adakveo market analysis highlights its size, growth potential, and segmentation, covering major regions and countries. Rising sickle cell disease prevalence, increasing healthcare expenditure, and innovative treatments are driving growth. Novartis AG leads, with North America as the largest market and Asia-Pacific fastest-growing. globenewswire.com - 2 weeks ago
Novartis to Acquire Regulus in $1.7 Billion Deal With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus. wsj.com - 2 weeks ago
Novartis to buy Regulus Therapeutics for up to $1.7 billion Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday. reuters.com - 2 weeks ago
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The agreed deal is fully in line with the therapeutic area focus of Novartis and leverages our strength and expertise in renal disease. globenewswire.com - 2 weeks ago
8. Profile Summary

Novartis AG NVS

image
COUNTRY CH
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 218 B
Dividend Yield 2.45%
Description Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Contact Lichtstrasse 35, Basel, 4056 https://www.novartis.com
IPO Date Nov. 7, 1996
Employees 75883
Officers Dr. Vasant Narasimhan M.D. Chief Executive Officer Dr. Patrick Horber M.D. President of International Ms. Karen L. Hale Chief Legal & Compliance Officer Paul Penepent Head of Group Financial Reporting and Accounting Dr. Steffen Lang Ph.D. President of Operations Ms. Sloan Simpson Global Head of Investor Relations Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer Mr. Harry Kirsch Chief Financial Officer Mr. Victor Bulto President of US Dr. Linda W. Armstrong M.D. Global Head of Respiratory Development